Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 19   

Articles published

KYTH 32.91 -0.67 (-2.00%)
price chart
KYTHERA Biopharmaceuticals to Release Second Quarter 2014 Operating ...
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Related articles »  
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New ...
CALABASAS, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S.
Related articles »  
Insider Selling: Nathaniel E. David Sells 1778 Shares of KYTHERA ...
Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
KYTHERA Biopharmaceuticals CEO Keith R. Leonard Unloads 8925 Shares ...
Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Related articles »  
Insider Selling: John W. Smither Unloads 2250 Shares of KYTHERA ...
On average, analysts predict that KYTHERA Biopharmaceuticals will post $-3.33 earnings per share for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Trader's Watch List � American Airlines (NASDAQ:AAL), Bed Bath & Beyond ...
KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) on 10 July announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S.
FDA Accepts Kythera Drug for Review
Kythera Biopharmaceuticals Inc. announced that the Food and Drug Administration has accepted its application for ATX-101, an experimental drug that dissolves chin fat.
Zeltiq Aesthetics Inc (ZLTQ) Earnings Report: Keeping Up Appearances? KYTH ...
The Q2 2014 earnings report for Zeltiq Aesthetics Inc (ZLTQ), a potential peer or benchmark for stocks like Kythera Biopharmaceuticals Inc (KYTH) and Cynosure, Inc (CYNO) that also focus on aesthetic applications like fat removal and/or plastic surgery ...
Drug Most Volatile Stocks: Heron Therapeutics (NASDAQ:HRTX), Tetraphase ...
On July 10, 2014, KYTHERA Biopharmaceuticals, Inc. issued a press release announcing that its New Drug Application for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S.
Leading Health Care Stock for Small-Cap Stars is Neuralstem Inc. (CUR) for ...
Investing in small-cap health care companies can be tricky, with stocks that can soar or crash based on the results of a single clinical trial.
Related articles »